These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 28884693)

  • 1. Why is survival after pembrolizumab affected by previous radiotherapy? - Authors' reply.
    Lee P; Shaverdian N
    Lancet Oncol; 2017 Sep; 18(9):e505. PubMed ID: 28884693
    [No Abstract]   [Full Text] [Related]  

  • 2. Why is survival after pembrolizumab affected by previous radiotherapy?
    Manapov F; Roengvoraphoj O; Eze C
    Lancet Oncol; 2017 Sep; 18(9):e504. PubMed ID: 28884692
    [No Abstract]   [Full Text] [Related]  

  • 3. Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer - Authors' reply.
    Zhu X; Cao Y; Zhang H
    Lancet Oncol; 2021 Oct; 22(10):e424. PubMed ID: 34592185
    [No Abstract]   [Full Text] [Related]  

  • 4. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
    Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
    J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NICE guidance on pembrolizumab for advanced melanoma.
    Watson I; Dominguez PP; Donegan E; Charles Z; Robertson J; Adam EJ
    Lancet Oncol; 2016 Jan; 17(1):21-2. PubMed ID: 26621380
    [No Abstract]   [Full Text] [Related]  

  • 8. Pembrolizumab in advanced head and neck cancer.
    Brower V
    Lancet Oncol; 2017 May; 18(5):e248. PubMed ID: 28366274
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
    Barone A; Hazarika M; Theoret MR; Mishra-Kalyani P; Chen H; He K; Sridhara R; Subramaniam S; Pfuma E; Wang Y; Li H; Zhao H; Zirkelbach JF; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Oct; 23(19):5661-5665. PubMed ID: 28179454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.
    González-Cao M; Arance A; Piulats JM; Marquez-Rodas I; Manzano JL; Berrocal A; Crespo G; Rodriguez D; Perez-Ruiz E; Berciano M; Soria A; Castano AG; Espinosa E; Montagut C; Alonso L; Puertolas T; Aguado C; Royo MA; Blanco R; Rodríguez JF; Muñoz E; Mut P; Barron F; Martin-Algarra S;
    Clin Transl Oncol; 2017 Jun; 19(6):761-768. PubMed ID: 28054320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
    Li D; He C; Xia Y; Du Y; Zhang J
    J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
    Sanlorenzo M; Vujic I; Daud A; Algazi A; Gubens M; Luna SA; Lin K; Quaglino P; Rappersberger K; Ortiz-Urda S
    JAMA Dermatol; 2015 Nov; 151(11):1206-1212. PubMed ID: 26222619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
    Schadendorf D; Dummer R; Hauschild A; Robert C; Hamid O; Daud A; van den Eertwegh A; Cranmer L; O'Day S; Puzanov I; Schachter J; Blank C; Salama A; Loquai C; Mehnert JM; Hille D; Ebbinghaus S; Kang SP; Zhou W; Ribas A
    Eur J Cancer; 2016 Nov; 67():46-54. PubMed ID: 27596353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraisal of the clinical effect of mepolizumab - Authors' reply.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A
    Lancet Respir Med; 2017 Jun; 5(6):e21. PubMed ID: 28664853
    [No Abstract]   [Full Text] [Related]  

  • 16. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab as second-line treatment for urothelial cancer.
    Mitchell F
    Lancet Oncol; 2017 Apr; 18(4):e197. PubMed ID: 28238595
    [No Abstract]   [Full Text] [Related]  

  • 18. A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
    Dagogo-Jack I; Lanfranchi M; Gainor JF; Giobbie-Hurder A; Lawrence DP; Shaw AT; Sullivan RJ
    J Immunother; 2017 Apr; 40(3):108-113. PubMed ID: 28221189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motavizumab, RSV, and subsequent wheezing - Authors' reply.
    O'Brien KL; Driscoll AJ; Santosham M; Hammitt LL; Karron RA
    Lancet Infect Dis; 2016 Dec; 16(12):1329-1330. PubMed ID: 27998592
    [No Abstract]   [Full Text] [Related]  

  • 20. ASPECCT: panitumumab versus cetuximab for colorectal cancer--authors' reply.
    Price TJ; Peeters M; Ruff P; Murugappan S; Sidhu R
    Lancet Oncol; 2014 Jul; 15(8):e303. PubMed ID: 24988928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.